Longbio reports positive data from allergic rhinitis therapy trial

Longbio Pharma (Suzhou) has reported positive topline results from a Phase I clinical trial of LP-003, a new long-acting anti-IgE antibody, for the treatment of allergic rhinitis.

The double-blind, randomised study has evaluated the pharmacokinetics, pharmacodynamics (free IgE levels) profile and safety of LP-003 in healthy subjects.